Immunotherapy in lung cancer: B7-bombers and other new developments

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 6, 2013, Pages 810-821

  Creelan, Ben C ^a   Antonia, Scott J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

cytotoxic T lymphocyte antigen 4 (CTLA 4); driver immunosuppressors; immunoediting; membrane associated glycoprotein (MUC 1); programmed cell death 1 (PD 1)

Indexed keywords

ADENOVIRUS VECTOR; AMP 224; ANTINEOPLASTIC AGENT; BELAGENPUMATUCEL L; BIOLOGICAL MARKER; BMS 936559; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DSB MPDL 3280A; EMEPEPIMUT S; GM CD40L BYTANDER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LAMBROLIZUMAB; LIRILUMAB; MELANOMA ANTIGEN 3; MK 3475; MPDL3280A; MUCIN 1; NIVOLUMAB; PEMETREXED; PEPTIDE VACCINE; PLASMID VECTOR; PROGRAMMED DEATH 1 LIGAND 1; RACOTUMOMAB; TECEMOTIDE; TG 4010; TG4010; TICILIMUMAB; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; URELIMAB;

ADVANCED CANCER; ANTIGEN PRESENTATION; ARM SWELLING; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CD8+ T LYMPHOCYTE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; DENDRITIC CELL; DISEASE FREE INTERVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ENCEPHALITIS; FATIGUE; GASTROINTESTINAL TOXICITY; GENE; GENE EXPRESSION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTE ACTIVATION GENE 3; MAINTENANCE CHEMOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POXVIRUS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FAMILY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; SOLID TUMOR; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIGENS, NEOPLASM; B7 ANTIGENS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PATIENT SELECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84888347627     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1358551     Document Type: Article

References (137)

1. Matsushita H., Vesely M. D., Koboldt D. C., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature: 2012; 482 7385 400 404
2. Derniame S., Vignaud J. M., Faure G. C., Béné M. C. Alteration of the immunological synapse in lung cancer: a microenvironmental approach. Clin Exp Immunol: 2008; 154 1 48 55
3. Kida H., Ihara S., Kumanogoh A. Involvement of STAT3 in immune evasion during lung tumorigenesis. OncoImmunology: 2013; 2 1 e22653
4. Schneider T., Hoffmann H., Dienemann H., et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol: 2011; 6 7 1162 1168
5. Sterlacci W., Wolf D., Savic S., et al. High transforming growth factor. β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol: 2012; 43 3 339 349
6. Salmon H., Donnadieu E. Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix. OncoImmunology: 2012; 1 6 992 994
7. Salmon H., Franciszkiewicz K., Damotte D., et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest: 2012; 122 3 899 910
8. Ramnath N., Tan D., Li Q., et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother: 2006; 55 8 891 899 (Pubitemid 43673578)
9. Lin A., Zhu C. C., Chen H. X., et al. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer. J Cell Mol Med: 2010; 14 9 2318 2329
10. Hanagiri T., Shigematsu Y., Kuroda K., et al. Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer. J Surg Res: 2013; 181 2 e57 e63
11. Woo E. Y., Yeh H., Chu C. S., et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol: 2002; 168 9 4272 4276 (Pubitemid 34441324)
12. Lesokhin A. M., Hohl T. M., Kitano S., et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res: 2012; 72 4 876 886
13. Nagaraj S., Youn J-I, Gabrilovich D. I. Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol: 2013; 191 1 17 23
14. Kelly R. J., Giaccone G. Lung cancer vaccines. Cancer J: 2011; 17 5 302 308
15. Erfani N., Mehrabadi S. M., Ghayumi M. A., et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer: 2012; 77 2 306 311
16. Li L., Chao Q. G., Ping L. Z., et al. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC. Cancer Biother Radiopharm: 2009; 24 3 357 367
17. Zatloukal P., Heo D., Park K., et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol: 2009; 27 (15S):abstract 8071
18. Lynch T. J., Bondarenko I., Luft A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol: 2012; 30 17 2046 2054
19. Wolchok J. D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res: 2009; 15 23 7412 7420
20. Genova C., Rijavec E., Barletta G., et al. Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. Expert Opin Biol Ther: 2012; 12 7 939 948
21. Reck M., Bondarenko I., Luft A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol: 2013; 24 1 75 83
22. Liu H., Zhang T., Ye J., et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother: 2012; 61 10 1849 1856
23. Reck M. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol: 2012; 23 08 viii28 34
24. Agata Y., Kawasaki A., Nishimura H., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol: 1996; 8 5 765 772 (Pubitemid 26148299)
25. Sauce D., Almeida J. R., Larsen M., et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS: 2007; 21 15 2005 2013 (Pubitemid 47462149)
26. Liang S. C., Latchman Y. E., Buhlmann J. E., et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol: 2003; 33 10 2706 2716 (Pubitemid 37337136)
27. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res: 2004; 10 15 5094 5100 (Pubitemid 39106851)
28. Sasaki H., Suzuki A., Shitara M., et al. PD-L1 gene expression in Japanese lung cancer patients. Biomedical Reports: 2013; 1 1 93 96
29. Velcheti V., Rimm D. L., Schalper K. A. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol: 2013; 8 6 803 805
30. Boland J. M., Kwon E. D., Harrington S. M., et al. Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung. Clin Lung Cancer: 2013; 14 2 157 163
31. Mu C-Y, Huang J-A, Chen Y., Chen C., Zhang X-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol: 2011; 28 3 682 688
32. Chen Y. B., Mu C. Y., Chen C., Huang J. A. Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population. Asia Pac J Clin Oncol: 2012; Nov 21. doi:10.1111/ajco.12037. [Epub ahead of print]
33. Chen C., Shen Y., Qu Q. X., Chen X. Q., Zhang X. G., Huang J. A. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res: 2013; 319 1 96 102
34. Zhang G., Xu Y., Lu X., et al. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer: 2009; 66 2 245 249
35. Sun Y., Wang Y., Zhao J., et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer: 2006; 53 2 143 151 (Pubitemid 43994236)
36. Zhou Y. H., Chen Y. J., Ma Z. Y., et al. 4IgB7-H3 is the major isoform expressed on immunocytes as well as malignant cells. Tissue Antigens: 2007; 70 2 96 104
37. Zhang Y., Huang S., Gong D., Qin Y., Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol: 2010; 7 5 389 395
38. Topalian S. L., Brahmer J. R., McDermott D. F., et al. Survival and Long-Term Safety in Cancer Patients Receiving the PD-1 Antibody Nivolumab. N Engl J Med: 2013;; In press
39. Rizvi N. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol: 2013; 31 (Suppl;):abstract 8072
40. Wolchok J. D., Kluger H., Callahan M. K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med: 2013; 369 2 122 133
41. Lipson E. J., Sharfman W. H., Drake C. G., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res: 2013; 19 2 462 468
42. Patnaik A., Kang S. P., Tolcher A. W., et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol: 2012; 30 (15S):abstract 2512
43. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med: 2013; 369 2 134 144
44. Beck A., Wurch T., Reichert J. M. Sixth Annual European Antibody Congress 2010: November 29-December 1, 2010; Geneva, Switzerland. MAbs: Austin, TX Landes Bioscience: 2011; 111 132
45. Mkrtichyan M., Najjar Y. G., Raulfs E. C., et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol: 2011; 41 10 2977 2986
46. Brahmer J. R., Tykodi S. S., Chow L. Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med: 2012; 366 26 2455 2465
47. Herbst R. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol: 2013; 31 (15S):abstract 3000
48. Powderly J. D. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J Clin Oncol: 2013; 31 (15S):abstract 3001
49. Mühlbauer M., Fleck M., Schütz C., et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-. α and -γ and mediates T cell apoptosis. J Hepatol: 2006; 45 4 520 528
50. Freidin M. B., Bhudia N., Lim E., Nicholson A. G., Cookson W. O., Moffatt M. F. Impact of collection and storage of lung tumor tissue on whole genome expression profiling. J Mol Diagn: 2012; 14 2 140 148
51. Mkrtichyan M. NY, Najjar Y. G., Raulfs E. C., et al. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol: 2012; 189 5 2338 2347
52. Smothers F., Hoos A., Langermann S., et al. AMP-224, a fusion protein that targets PD-1. Ann Oncol: 2013; 24 01 i7 i17
53. Infante J. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J Clin Oncol: 2013; 31 (15S):abstract 3044
54. Jacobs R., Hintzen G., Kemper A., et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol: 2001; 31 10 3121 3127
55. Carrega P., Morandi B., Costa R., et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer: 2008; 112 4 863 875 (Pubitemid 351240580)
56. Al Omar S., Middleton D., Marshall E., et al. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol: 2010; 71 10 976 981
57. Al Omar S. Y., Marshall E., Middleton D., Christmas S. E. Increased numbers but functional defects of CD56+CD3+ cells in lung cancer. Int Immunol: 2012; 24 7 409 415
58. Al Omar S. Y., Marshall E., Middleton D., Christmas S. E. Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology: 2011; 133 1 94 104
59. Dorothée G., Echchakir H., Le Maux Chansac B., et al. Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma. Oncogene: 2003; 22 46 7192 7198 (Pubitemid 37378551)
60. Wiśniewski A., Jankowska R., Passowicz-Muszyńska E., et al. KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population. Hum Immunol: 2012; 73 9 927 931
61. Sanborn R. A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. J Clin Oncol: 2013; 31 (15S):abstract TPS3110
62. Rizvi N. A., Infante J. R., Gibney G. T., et al. A Phase I Study of Lirilumab (BMS-986015), an Anti-KIR Monoclonal Antibody, Administered with Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Select Advanced Solid Tumors. J Clin Oncol: 2013; 31 (15S):abstract TPS3106
63. Sznol M., Hodi F., Margolin K., et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol: 2008; 26 (15S):abstract 3007
64. Matsuzaki J., Gnjatic S., Mhawech-Fauceglia P., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A: 2010; 107 17 7875 7880
65. Okazaki T., Okazaki I. M., Wang J., et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med: 2011; 208 2 395 407
66. Woo S-R, Turnis M. E., Goldberg M. V., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res: 2012; 72 4 917 927
67. Brunsvig P. F., Kyte J. A., Kersten C., et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res: 2011; 17 21 6847 6857
68. Dalyot-Herman N., Bathe O. F., Malek T. R. Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J Immunol: 2000; 165 12 6731 6737 (Pubitemid 32001136)
69. Boczkowski D., Nair S. K., Snyder D., Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med: 1996; 184 2 465 472 (Pubitemid 26324100)
70. Chiodoni C., Paglia P., Stoppacciaro A., Rodolfo M., Parenza M., Colombo M. P. Dendritic cells infiltrating tumors cotransduced with granulocyte/ macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med: 1999; 190 1 125 133 (Pubitemid 29330129)
71. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med: 1994; 179 4 1109 1118
72. Salgia R., Lynch T., Skarin A., et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol: 2003; 21 4 624 630 (Pubitemid 46621895)
73. Nemunaitis J., Vorhies J. S., Pappen B., Senzer N. 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Ther: 2007; 14 8 762 763 (Pubitemid 47080358)
74. Nemunaitis J., Sterman D., Jablons D., et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst: 2004; 96 4 326 331 (Pubitemid 38256277)
75. Borrello I., Sotomayor E. M., Cooke S., Levitsky H. I. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther: 1999; 10 12 1983 1991 (Pubitemid 29387912)
76. Nemunaitis J., Jahan T., Ross H., et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther: 2006; 13 6 555 562
77. Morales J. K., Kmieciak M., Knutson K. L., Bear H. D., Manjili M. H. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat: 2010; 123 1 39 49
78. Serafini P., Carbley R., Noonan K. A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res: 2004; 64 17 6337 6343 (Pubitemid 39129439)
79. Morse M. A., Hobeika A. C., Osada T., et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood: 2008; 112 3 610 618
80. Nicholaou T., Ebert L. M., Davis I. D., et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res: 2009; 15 6 2166 2173
81. Antonia S. J., Mule J. J. Chemokine gene-modified cells for cancer immunotherapy. United States Patent Application 20130251752, Publication Date: Sept 2013. Available at: http://www.freepatentsonline.com/y2013/0251752.html
82. Wroblewski J. M., Bixby D. L., Borowski C., Yannelli J. R. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer: 2001; 33 2-3 181 194 (Pubitemid 32707899)
83. Michael A., Ball G., Quatan N., et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res: 2005; 11 12 4469 4478 (Pubitemid 40825637)
84. Bercovici N., Haicheur N., Massicard S., et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother: 2008; 31 1 101 112 (Pubitemid 351619409)
85. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med: 1996; 184 2 747 752 (Pubitemid 26324129)
86. Dessureault S., Alsarraj M., McCarthy S., et al. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res: 2005; 125 2 173 181 (Pubitemid 40602390)
87. Dessureault S., Noyes D., Lee D., et al. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol: 2007; 14 2 869 884 (Pubitemid 46175338)
88. Yousefieh N., Hahto S. M., Stephens A. L., Ciavarra R. P. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron: 2009; 2 1 59 67
89. Hall R. D., Gray J. E., Chiappori A. A. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control: 2013; 20 1 22 31
90. Nemunaitis J., Dillman R. O., Schwarzenberger P. O., et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol: 2006; 24 29 4721 4730 (Pubitemid 46630936)
91. Derynck R., Akhurst R. J., Balmain A. TGF-. β signaling in tumor suppression and cancer progression. Nat Genet: 2001; 29 2 117 129
92. Weiss A., Attisano L. The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol: 2013; 2 1 47 63
93. Saji H., Nakamura H., Awut I., et al. Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg: 2003; 9 5 295 300
94. Vujaskovic Z., Groen H. J. TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol: 2000; 76 4 511 516 (Pubitemid 30232450)
95. Nemunaitis J., Nemunaitis M., Senzer N., et al. Phase II trial of Belagenpumatucel-L, a TGF-. β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther: 2009; 16 8 620 624
96. INSPIRE. Is the Lucanix Phase 3 Trial Over? 2012. http://www.inspire.com/ groups/lung-cancer-survivors/discussion/is-lucanix-phase-3-trial-over/. Accessed June 2013
97. Fakhrai H. ClinicalTrials.gov. Phase III study of Lucanix (belagenpumatucel-L) in advanced non-small cell lung cancer. NCT 00676507. http://clinicaltrials.gov/show/NCT00676507. Accessed July 2013
98. Finn O. J., Jerome K. R., Henderson R. A., et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev: 1995; 145 1 61 89
99. Bansal A. S., Bruce J., Devine P. L., Scells B., Zimmermann P. V. Serum cytokines and tumour markers in patients with non-small cell carcinoma of the lung. Dis Markers: 1997; 13 3 195 199 (Pubitemid 27494089)
100. Lloyd K. O., Burchell J., Kudryashov V., Yin B. W., Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines: demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem: 1996; 271 52 33325 33334 (Pubitemid 27010142)
101. Dahiya R., Kwak K-S, Byrd J. C., Ho S., Yoon W. H., Kim Y. S. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene. Cancer Res: 1993; 53 6 1437 1443 (Pubitemid 23097129)
102. Spicer A. P., Rowse G. J., Lidner T. K., Gendler S. J. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem: 1995; 270 50 30093 30101 (Pubitemid 26001684)
103. Rochlitz C., Figlin R., Squiban P., et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med: 2003; 5 8 690 699 (Pubitemid 40309707)
104. Butts C., Murray R. N., Smith C. J., et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer: 2010; 11 6 391 395
105. Butts C., Maksymiuk A., Goss G., et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol: 2011; 137 9 1337 1342
106. Butts C. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol: 2013; 31 (15S):abstract 7500
107. Limacher J-M, Spring-Giusti C., Bellon N., Ancian P., Rooke R., Bonnefoy J. Y. Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer. Expert Rev Vaccines: 2013; 12 3 263 270
108. Quoix E., Ramlau R., Westeel V., et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol: 2011; 12 12 1125 1133
109. Ramlau R., Quoix E., Rolski J., et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol: 2008; 3 7 735 744
110. Nemunaitis J. Cancer targeting vaccines: surrogate measures of activity. Hum Vaccin Immunother: 2013; 9 1 213 218
111. Quoix E. A., Nemunaitis J. J., Burzykowski T., Bastien B., Lacoste G. TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC). J Clin Oncol: 2012; 30 (15S):abstract TPS7610
112. Gure A. O., Chua R., Williamson B., et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res: 2005; 11 22 8055 8062 (Pubitemid 41698748)
113. Sienel W., Varwerk C., Linder A., et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg: 2004; 25 1 131 134 (Pubitemid 38019071)
114. Vantomme V., Dantinne C., Amrani N., et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother: 2004; 27 2 124 135 (Pubitemid 38282732)
115. Schultz E. S., Lethé B., Cambiaso C. L., et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res: 2000; 60 22 6272 6275
116. Gaugler B., Van den Eynde B., van der Bruggen P., et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med: 1994; 179 3 921 930 (Pubitemid 24065650)
117. Vansteenkiste J., Zielinski M., Linder A., et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol: 2007; 25 (18S):abstract 7554
118. Vansteenkiste J., Zielinski M., Dahabreh I., et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigenspecific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol: 2008; 26 (15S):abstract 7501
119. Atanackovic D., Altorki N. K., Cao Y., et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A: 2008; 105 5 1650 1655 (Pubitemid 351346569)
120. Atanackovic D., Altorki N., Cao Y., et al. Booster vaccination of non-small cell lung cancer (NSCLC) patients with MAGEA3 protein and AS02B adjuvant. In ASCO Annual Meeting Proceedings Part I. J Clin Oncol: 2007; 25 (18S):abstract 3015
121. De Pas T., Kim J-H, Zarogoulidis K., et al. MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized. J Thorac Oncol: 2009; 4 9 S331 S332
122. Tyagi P., Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer: 2009; 10 5 371 374
123. Hobohm K., Seppmann T., Britten C. M., Hoff H. Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany. Cancer Immunol Immunother: 2012; 61 1 137 143
124. van Cruijsen H., Ruiz M. G., van der Valk P., de Gruijl T. D., Giaccone G. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer: 2009; 9 1 180
125. Blanco R., Rengifo C. E., Cedeño M., Frómeta M., Rengifo E., Carr A. Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Patholog Res Int: 2012;;2012:235418. doi:10.1155/2012/235418. Epub 2012 Feb 26
126. de Leòn J., Fernández A., Mesa C., Clavel M., Fernández L. E. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother: 2006; 55 4 443 450 (Pubitemid 43076896)
127. Gomez D. E., Vázquez A. M., Alonso D. F., Macías A. Anti-idiotype antibodies in cancer treatment. Front Oncol: 2013; 3 37. doi:10.3389/fonc.2013.00037
128. Shaw A. T., Yeap B. Y., Solomon B. J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol: 2011; 12 11 1004 1012
129. Paez J. G., Jänne P. A., Lee J. C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science: 2004; 304 5676 1497 1500 (Pubitemid 38720929)
130. Sloan J. A., Cella D., Frost M., Guyatt G. H., Sprangers M., Symonds T.; Clinical Significance Consensus Meeting Group. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc: 2002; 77 4 367 370 (Pubitemid 34260745)
131. Mina L. A., Sledge G. W. Jr. Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol: 2011; 8 6 325 332
132. Sledge G. W. Jr. The challenge and promise of the genomic era. J Clin Oncol: 2012; 30 2 203 209
133. Ocaña A., Amir E., Vera F., Eisenhauer E. A., Tannock I. F. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol: 2011; 29 3 254 256
134. Niraula S., Seruga B., Ocana A., et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol: 2012; 30 24 3012 3019
135. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol: 2011; 12 10 933 980
136. Ribas A., Hersey P., Middleton M. R., et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res: 2012; 18 2 336 341
137. Stewart R., Mulgrew K., Wang S., et al. Blockade of PD-L1 Mediated Immunosupression for Cancer Therapy-MEDI4736, Monoclonal Antibody Discovery and Preclinical Development [abstract from 27th Annual Scientific Meeting of the Society for Immunotherapy of Cancer]. J Immunother: 2012; 35 9S 765 766